EUVIMEDEUVIMED entdecken
Crossref

BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model

Fereshteh Moheb Afzali, Masoumeh Heshmati, Ali Salimi, Somayeh Kalanaky, Saideh Fakharzadeh, Maryam Hafizi, Mohammad Esmail Akbari, Mohammad Hassan Nazaran, Mehrdad Hashemi

Archives of Advances in Biosciences · 01.05.2026

DOI: 10.22037/aab.v16i1.52004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Advances in Biosciences, erschienen am 01.05.2026. Verfasst von Fereshteh Moheb Afzali und 8 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim: Breast cancer remains a major cause of cancer mortality in women, and tumor-driven cytokine dysregulation promotes immune escape. This study aimed to define the splenic immunomodulatory activity of BCc1 nanomedicine in 4T1 breast tumor-bearing BALB/c mice by measuring interleukin-12 (IL-12), transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α), and the (TGF-β1)⁄(IL-12) balance.

Methods

Seventy female mice with palpable tumors received a 24-day regimen of intraperitoneal or oral BCc1, cyclophosphamide, or phosphate-buffered saline (PBS). Splenic cytokines were quantified by ELISA, and the (TGF-β1)⁄(IL-12) ratio was calculated as an index of cytokine polarization.

Results

BCc1 reshaped splenic cytokine patterns in a dose- and route-dependent manner. High-dose intraperitoneal BCc1 produced the strongest effects, markedly reducing and , inducing controlled modulation of , and substantially lowering the ratio. These changes indicate reduced immunoregulatory dominance and a shift toward an antitumor-permissive cytokine milieu. For several cytokine endpoints, high-dose BCc1 showed effects comparable to or greater than cyclophosphamide. Oral BCc1 elicited milder dose-dependent responses, with stronger immunomodulation at the higher oral dose.

Conclusion

BCc1 therefore mediates route- and dose-dependent splenic cytokine remodeling, supporting further evaluation as a multifunctional immunomodulatory nanotherapeutic; cellular phenotyping and functional antitumor assays are required to determine whether these cytokine shifts translate into immune-mediated tumor control Background and Aim: Breast cancer remains a major cause of cancer mortality in women, and tumor-driven cytokine dysregulation promotes immune escape. This study aimed to define the splenic immunomodulatory activity of BCc1 nanomedicine in 4T1 breast tumor-bearing BALB/c mice by measuring interleukin-12 (IL-12), transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α), and the (TGF-β1)⁄(IL-12) balance.

Methods

Seventy female mice with palpable tumors received a 24-day regimen of intraperitoneal or oral BCc1, cyclophosphamide, or phosphate-buffered saline (PBS). Splenic cytokines were quantified by ELISA, and the (TGF-β1)⁄(IL-12) ratio was calculated as an index of cytokine polarization.

Results

BCc1 reshaped splenic cytokine patterns in a dose- and route-dependent manner. High-dose intraperitoneal BCc1 produced the strongest effects, markedly reducing and , inducing controlled modulation of , and substantially lowering the ratio. These changes indicate reduced immunoregulatory dominance and a shift toward an antitumor-permissive cytokine milieu. For several cytokine endpoints, high-dose BCc1 showed effects comparable to or greater than cyclophosphamide. Oral BCc1 elicited milder dose-dependent responses, with stronger immunomodulation at the higher oral dose.

Conclusion

BCc1 therefore mediates route- and dose-dependent splenic cytokine remodeling, supporting further evaluation as a multifunctional immunomodulatory nanotherapeutic; cellular phenotyping and functional antitumor assays are required to determine whether these cytokine shifts translate into immune-mediated tumor control

Schlagwörter

nanomedicinebreast cancerantitumor immunityinnate immunitysplenic cytokinesTh1/Th2 balancecyclophosphamide4T1 tumor modelimmunomodulationoral administration

Zitieren

APA

Afzali, F. M., Heshmati, M., Salimi, A., Kalanaky, S., Fakharzadeh, S., Hafizi, M., Akbari, M. E., Nazaran, M. H., & Hashemi, M. (2026). BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model. Archives of Advances in Biosciences. https://doi.org/10.22037/aab.v16i1.52004

Vancouver

Afzali FM, Heshmati M, Salimi A, Kalanaky S, Fakharzadeh S, Hafizi M, et al. BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model. Archives of Advances in Biosciences. 2026. doi:10.22037/aab.v16i1.52004

BibTeX
@article{Afzali2026,
  author = {Afzali, Fereshteh Moheb and Heshmati, Masoumeh and Salimi, Ali and Kalanaky, Somayeh and Fakharzadeh, Saideh and Hafizi, Maryam and Akbari, Mohammad Esmail and Nazaran, Mohammad Hassan and Hashemi, Mehrdad},
  title = {BCc1 Nanomedicine Modulates Splenic Cytokine Networks to Enhance Antitumor Innate Immunity in a Murine Breast Cancer Model},
  journal = {Archives of Advances in Biosciences},
  year = {2026},
  doi = {10.22037/aab.v16i1.52004}
}
Kostenlos starten →